I have offered a couple of suggestions, which you identified before, so I won't repeat those. I would like people to look at the act as a safeguard to ensure that patents are being used responsibly, to ensure that the R and D industry is doing what it needs to do to make sure its products are affordable in the developing world. I don't think the act should be looked at as a mechanism to override patent protections.
We are very committed to access in the developing world, as is our industry. We spend tens of millions of dollars a year in the developing world running clinical trials to determine the appropriate use of our products, as well as through our programs, which we operate at substantial losses. This is something we are committed to and will remain committed to, and we want the opportunity to work in this area.